25E-NBF
25E-NBF is a synthetic compound that belongs to the class of phenethylamines, specifically a derivative of the 2C family of psychedelic substances. It is structurally related to the more well-known compound 25I-NBOMe, which is a potent agonist of the 5-HT2A receptor and is known for its psychedelic effects.
Chemical Structure and Properties[edit | edit source]
25E-NBF is chemically known as 2-(4-ethoxy-2,5-dimethoxyphenyl)-N-(2-fluorobenzyl)ethanamine. It features a phenethylamine core with a 2,5-dimethoxy substitution pattern on the phenyl ring, an ethoxy group at the 4-position, and a fluorobenzyl group attached to the nitrogen atom.
Molecular Formula: C19H24FNO3
Molecular Weight: 333.40 g/mol
Pharmacology[edit | edit source]
25E-NBF is believed to act as a potent agonist at the 5-HT2A receptor, similar to other compounds in the NBOMe series. This receptor is a subtype of the serotonin receptor and is primarily responsible for the psychedelic effects of these substances. The binding affinity and efficacy of 25E-NBF at this receptor, however, have not been extensively studied.
Effects[edit | edit source]
The effects of 25E-NBF are largely anecdotal and based on user reports, as there is limited scientific research on this compound. Users have reported experiencing:
- Visual and auditory hallucinations
- Altered perception of time and space
- Euphoria and mood enhancement
- Increased introspection and philosophical thinking
Due to its potency, 25E-NBF can produce these effects at very low doses, which increases the risk of overdose and adverse reactions.
Risks and Safety[edit | edit source]
The safety profile of 25E-NBF is not well-established. However, compounds in the NBOMe series are known to have a high potential for toxicity, especially at higher doses. Reported adverse effects include:
- Severe vasoconstriction
- Hypertension
- Tachycardia
- Seizures
- Agitation and confusion
Due to these risks, the use of 25E-NBF is discouraged outside of a controlled research setting.
Legal Status[edit | edit source]
The legal status of 25E-NBF varies by country. In many jurisdictions, it is considered a controlled substance due to its structural similarity to other banned NBOMe compounds. Users should be aware of the legal implications of possessing or distributing this substance.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD